The CancerSEEK blood test, developed by scientists at Baltimore-based Johns Hopkins University, screens for 16 genes and nine protein markers that may indicate the presence of cancer.
To assess CancerSEEK’s safety and efficacy, Geisinger researchers conducted blood testing on 10,006 female patients with no past history of cancer. They identified 26 cancers through testing, which were confirmed by PET or CT scans. The test also demonstrated a low rate of false positives.
The findings suggest the CancerSEEK test could be used as a complement to standard cancer screening processes to help detect cancer before it spreads. The test could also improve screening for conditions like ovarian cancer, as standard screening tests for this type of cancer do not exist.
More articles on patient safety and outcomes:
One-third of COVID-19 patients in New York study received invasive ventilation
Ventilators should be used sparingly for COVID-19 patients, researchers warn
What EHR data reveals about ventilated COVID-19 patients at 12 New York hospitals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
